Suppr超能文献

尾加压素II在中枢起作用,增加肾上腺素和促肾上腺皮质激素释放,并引起有效的变力性和变时性作用。

Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions.

作者信息

Watson Anna M D, Lambert Gavin W, Smith Kathryn J, May Clive N

机构信息

Howard Florey Institute, University of Melbourne, Victoria 3010, Australia.

出版信息

Hypertension. 2003 Sep;42(3):373-9. doi: 10.1161/01.HYP.0000084633.85427.E6. Epub 2003 Jul 28.

Abstract

Urotensin II is a small peptide whose receptor was recently identified in mammals as the orphan G protein-coupled receptor-14. The reported cardiovascular responses to systemic urotensin II administration are variable, and there is little detailed information on its central cardiovascular actions. We examined the cardiovascular and humoral actions of intracerebroventricular urotensin II (0.02 and 0.2 nmol/kg and vehicle) and intravenous urotensin II (2, 20, and 40 nmol/kg and vehicle) in conscious ewes previously surgically implanted with flow probes and intracerebroventricular guide tubes. Two hours after intracerebroventricular infusion of urotensin II (0.2 nmol/kg over 1 hour; n=5), heart rate (+56+/-13 beats per minute [bpm]), dF/dt (an index of cardiac contractility; +533+/-128 L x min(-1) x s(-1)), and cardiac output (+3.4+/-0.4 L/min) increased significantly compared with vehicle, as did renal, mesenteric, and iliac blood flows and conductances. Plasma epinephrine, adrenocorticotropic hormone, and glucose levels also increased dramatically (+753+/-166 pg/mL, +14.3+/-3.5 pmol/L, and +7.0+/-1.4 mmol/L, respectively). All of these variables remained elevated for up to 4 hours after infusion. In contrast, 1 hour after intravenous urotensin II (40 nmol/kg bolus; n=6), a sustained tachycardia (+25+/-8 bpm) ensued, but cardiac output, cardiac contractility, total peripheral conductance, and plasma glucose levels did not change significantly. In summary, this is the first study to show that urotensin II acts centrally to stimulate sympathoadrenal and pituitary-adrenal pathways, resulting in increased adrenocorticotropic hormone and epinephrine release and potent chronotropic and inotropic actions. In contrast, tachycardia was the only major response to intravenous urotensin II. These findings suggest that urotensin II is a novel stimulator of central pathways that mediate responses to alerting stimuli or stress.

摘要

尾加压素II是一种小肽,其受体最近在哺乳动物中被鉴定为孤儿G蛋白偶联受体-14。报道的全身给予尾加压素II后的心血管反应各不相同,关于其对中枢心血管的作用的详细信息很少。我们研究了脑室内注射尾加压素II(0.02和0.2 nmol/kg以及溶剂)和静脉注射尾加压素II(2、20和40 nmol/kg以及溶剂)对先前通过手术植入流量探头和脑室内导管的清醒母羊的心血管和体液作用。脑室内注入尾加压素II(0.2 nmol/kg,持续1小时;n = 5)2小时后,心率(每分钟增加56±13次心跳 [bpm])、dF/dt(心脏收缩性指标;增加533±128 L×min⁻¹×s⁻¹)和心输出量(增加3.4±0.4 L/min)与溶剂相比显著增加,肾、肠系膜和髂血流量及血管传导率也增加。血浆肾上腺素、促肾上腺皮质激素和葡萄糖水平也显著升高(分别为+753±166 pg/mL、+14.3±3.5 pmol/L和+7.0±1.4 mmol/L)。输注后所有这些变量在长达4小时内都保持升高。相比之下,静脉注射尾加压素II(40 nmol/kg推注;n = 6)1小时后,出现持续心动过速(增加25±8 bpm),但心输出量、心脏收缩性、总外周传导率和血浆葡萄糖水平没有显著变化。总之,这是第一项表明尾加压素II在中枢起作用以刺激交感肾上腺和垂体 - 肾上腺途径,导致促肾上腺皮质激素和肾上腺素释放增加以及强效变时和变力作用的研究。相比之下,心动过速是静脉注射尾加压素II的唯一主要反应。这些发现表明尾加压素II是介导对警觉刺激或应激反应的中枢途径的新型刺激物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验